<div>An experimental medication slows the progression of the neurodegenerative disease called Amyotrophic lateral sclerosis (ALS), or Lou Gehrig's disease, according to recently released results from a clinical trial run by investigators at the Sean M. Healey &amp; AMG Center for ALS at Massachusetts General Hospital and Amylyx Pharmaceuticals, Inc., the company that manufactures the medication.</div>